Treatment Landscape for Acute Myeloid Leukemia Appears Hopeful for Patients

July 31, 2020

Eunice Wang, MD, discusses the excitement she has experienced in the treatment landscape of acute myeloid leukemia over the last several years due to the number of new treatment options approved by the FDA.

Hyper-CVAD Plus Ofatumumab Demonstrates Activity in Ph-Negative, CD20-Positive B-Cell ALL

July 15, 2020

“In this single-arm, phase 2 study, the combination of ofatumumab with the hyper-CVAD regimen resulted in a high proportion of adult patients with Ph-negative CD20- positive B-cell acute lymphoblastic leukemia having durable remission and long-term survival…"

Phase 3 Study Confirms Benefit of Venetoclax/LDAC in Chemotherapy-Ineligible AML

July 03, 2020

A new randomized placebo-controlled study finds patients with acute myeloid leukemia who cannot undergo intensive chemotherapy have improved outcomes when given venetoclax in addition to low-dose cytarabine.

Discontinuation of Venetoclax Impacts Outcomes of Rituximab Combination in CLL

June 25, 2020

In an interview with Targeted Oncology, Anthony Mato, MD, discussed the findings of venetoclax interruptions or discontinuations observed in patients with relapsed/refractory chronic lymphocytic leukemia who received the combination of venetoclax plus rituximab in the phase 3 MURANO study.

Complex Karyotype Strongly Associated With Shorter PFS in Chronic Lymphocytic Leukemia

June 25, 2020

All patients with relapsed/refractory chronic lymphocytic leukemia should be evaluated for both complex karyotypes and del17p prior to initiating treatment, and all patients with complex karyotypes should be considered candidates for alternative combination therapy.

Managing Patients With Myeloid Malignancies During and After the Global COVID-19 Pandemic

June 24, 2020

During the Virtual 25th Congress of the European Hematology Association (EHA), a group of physicians described their experiences and recommendations for managing patients with myeloid malignancies during the COVID-19 pandemic and after.

Disparities Seen in Hematologic Cancer Incidence and Survival for Hispanic Patients in Texas

June 22, 2020

“[This] report on the diagnosis of blood cancers in the US/Mexico border inure the different frequency of leukemia subtypes and their outcomes, highlighting important health disparities due to different access to diagnosis and care due to a series of factors."

Ublituximab Plus Ibrutinib Induces Promises Responses in High-Risk Relapsed/Refractory CLL

June 11, 2020

In an interview with Targeted Oncology, Jeff P. Sharman, MD, discussed the findings for the combination of ublituximab plus ibrutinib as treatment of patients with high-risk relapsed/refractory chronic lymphocytic leukemia.

Real-World MRD Responses Observed With NGS in Acute Lymphoblastic Leukemia and Other Lymphoid Cancers

May 27, 2020

"The ability for NGS to assess response across a continuum of relevant MRD threshold levels is an important consideration for applying MRD testing in clinical practice."

Analyzing CAR T-Cell Neurotoxicity in Adult Patients With ALL

May 18, 2020

Jae Park, MD, discusses adverse events associated with chimeric antigen receptor T-cell therapies, such as neurotoxicity, for patients with acute lymphocytic leukemia.